News in other languages: NEOVACS

30/06	Neovacs renforce son portefeuille stratégique de propriété intellectuelle
30/06	Neovacs : Neovacs renforce son portefeuille stratégique de propriété intellectuelle avec le dépôt d’une demande de brevet couvrant une nouvelle famille de lipides dédiés à la délivrance d’ARN
29/06	Neovacs : Cotation des actions Néovacs regroupées
15/06	Financements dilutifs et fonds vautours : le législateur s'en mêle enfin
22/05	Bourse : Richemont brille, Estée Lauder renonce à Puig, Kioxia grossit

More news

Managers and Directors: NEOVACS

Manager	Title	Age	Since
Hugo Brugière CEO	Chief Executive Officer	-	-
Alexandre Courtoux DFI	Director of Finance/CFO	-	01/10/2020
Laurent Reber CTO	Chief Tech/Sci/R&D Officer	56	-

Director	Title	Age	Since
Jean-Jacques Bertrand CHM	Chairman	87	28/05/2003
Baudouin Hallo BRD	Director/Board Member	-	01/05/2020
Hugo Brugière CHM	Chairman	-	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEOVACS	-1.00%	-1.00%	-	-	2L
LONZA GROUP AG	+0.58%	+2.06%	+2.92%	+10.86%	5.04TCr
REVOLUTION MEDICINES, INC.	-2.03%	-1.70%	+385.09%	+586.37%	4.06TCr
IQVIA HOLDINGS INC.	-0.62%	+0.69%	+25.29%	-5.49%	3.49TCr
BEONE MEDICINES AG	-1.18%	-3.76%	+17.54%	+54.69%	3.37TCr
CELLTRION, INC.	+1.21%	-0.79%	+4.46%	+35.18%	2.63TCr
ASCENDIS PHARMA A/S	-2.23%	+0.25%	-	-	1.71TCr
MEDPACE HOLDINGS, INC.	+0.10%	-5.51%	+62.68%	+120.84%	1.53TCr
IONIS PHARMACEUTICALS, INC.	-7.97%	-29.15%	+39.05%	+41.05%	1.06TCr
EUROFINS SCIENTIFIC SE	+0.23%	-0.58%	+13.76%	+21.11%	1.37TCr
Average	-1.27%	-2.12%	+68.85%	+108.08%	2.7TCr
Weighted average by Cap.	-0.78%	-0.03%	+84.00%	+130.88%

See all sector performances

NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

30/06	Neovacs bolsters its strategic intellectual property portfolio
11/02	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI

Market Cap	4.09T 4.67T 3.77T 3.48T 6.61T 4L 6.72T 45.06T 17.7T 2L 17.55T 17.17T 8L	P/E 2023 *	-	P/E 2024	-
Enterprise Value	-2L -2L -2L -2L -3L -2.19Cr -3L -22.15L -9L -1.08Cr -9L -8L -3.71Cr	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	99%	Yield 2023 *	-	Yield 2024	-

30/06	Neovacs bolsters its strategic intellectual property portfolio
11/02	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
21/11	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
21/25/21	Neovacs S.A. announced that it expects to receive ?0.25 million in funding	CI
12/25/12	Neovacs S.A. announced that it has received ?0.25 million in funding from European High Growth Opportunities Manco S.A.	CI
30/25/30	Neovacs S.A. Auditor Raises 'Going Concern' Doubt	CI
30/25/30	Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
17/25/17	Neovacs S.A. announced a financing transaction	CI
04/25/04	Neovacs: consideration of delisting, share price surges
04/24/04	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
01/24/01	Tech's Tangled Path with Microsoft
17/24/17	Neovacs: collaboration agreement with CNRS
10/24/10	Neovacs: presents results from vaccine candidates

	2023	2024
Net sales	5L 6L 5L 5L 9L 5.82Cr 9L 58.79L 23.09L 2.87Cr 22.9L 22.4L 9.85Cr	4L 5L 4L 4L 7L 4.73Cr 7L 47.82L 18.78L 2.33Cr 18.63L 18.22L 8.01Cr
Net income	-87.43L -99.96L -80.65L -74.49L -1.41Cr -95Cr -1.44Cr -9.64Cr -3.78Cr -47Cr -3.75Cr -3.67Cr -161.46Cr	-3.29Cr -3.76Cr -3.04Cr -2.8Cr -5.32Cr -358.89Cr -5.41Cr -36Cr -14Cr -176.8Cr -14Cr -14Cr -607.8Cr
Net Debt	-2L -3L -2L -2L -4L -2.58Cr -4L -26.06L -10.24L -1.27Cr -10.15L -10L -4.37Cr	-2L -2L -2L -2L -3L -2.24Cr -3L -22.6L -9L -1.1Cr -9L -9L -3.79Cr

NEOVACS Share Price Euronext Paris

Stocks

ALNEV

FR001400HDX0

Biotechnology & Medical Research

Valuation: NEOVACS

Latest news : NEOVACS

News in other languages: NEOVACS

Quotes and Performance

Managers and Directors: NEOVACS

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

End-of-day quote Euronext Paris Other stock markets 05/02/2024			5-day change	1st Jan Change
1.980 ^EUR	-1.00%		-1.00%	-1.00%